Third Circuit rescues Fresenius Kabi’s monopolisation claims against Par

Alex Wilts

13 January 2021

Shutterstock/JHVEPhoto

An appellate court has revived drug manufacturer Fresenius Kabi’s antitrust lawsuit against Par Pharmaceutical, determining that a lower court in New Jersey failed to conduct a requisite analysis of the issues in the case.

Subscribe to Global Competition Review

Subscribe to unlock unlimited access

Get news, unique commentary, expert analysis and essential resources from the Global Competition Review experts.

Subscribe now

Already have access? Login below

Alex Wilts

View full biography

Author | Editor, GCR USA

[email protected]

Tipline

Could have been an email: The Tipline for 1 December 2023
The Federal Trade Commission and House Judiciary Committee appear to be stuck in a stalemate regardless of whether their quarrel occurs in letters or public hearings. Pressed by Republican lawmakers about the FTC’s responses (or lack thereof) to various document demands, the commission’s director of congressional relations had very little to say. “I’m not able to provide that information today, but we're happy to continue talking to your staff,” Jeanne Bumpus said.
Take two: The Tipline for 30 November 2023
Lights, in camera, action: The Tipline for 29 November 2023

Third Circuit rescues Fresenius Kabi’s monopolisation claims against Par

Subscribe to Global Competition Review

Subscribe to unlock unlimited access

Already have access? Login below

Related Topics

Alex Wilts